Trial site
Emek Medical Center
- 14running trials
- 6closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Conditions
- Lung cancer3 trials
- Obesity3 trials
- Multiple myeloma2 trials
- Type 1 diabetes2 trials
- Type 2 diabetes2 trials
- Alopecia areata1 trial
- Atopic dermatitis (eczema)1 trial
- Chronic kidney disease1 trial
- Coronary artery disease1 trial
- Crohn's disease1 trial
- Fatty liver disease (MASLD/MASH)1 trial
- Gout1 trial
- and 4 more
- Phase
- Phase 311 trials
- Phase 24 trials
- Phase 2/33 trials
- Status
- Active, not recruiting7 trials
- Recruiting6 trials
- Completed5 trials
- Not yet recruiting1 trial
- Withdrawn1 trial
- Lead sponsor
- Eli Lilly and Company6 trials
- Karyopharm Therapeutics Inc2 trials
- CSL Behring1 trial
- Guy Schusheim1 trial
- HaEmek Medical Center, Israel1 trial
- and 9 more
Running trials
Recruiting
Recruiting
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Recruiting
Decoding the Clinical Impact of Host and Microbial Intestinal Proteomic Landscape in Crohn's Disease
Active, not recruiting
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
Active, not recruiting
Recruiting
Preliminary Effectiveness of Hybrid Individual and Group MDMA-assisted Therapy for War-related PTSD
Recruiting
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
Recruiting
Recruiting
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer2 recruiting
- Crohn's disease1 recruiting
- Gout1 recruiting
- Obesity1 recruiting
- Type 2 diabetes1 recruiting
Closed trials
Recruiting
Recruiting
Completed
Completed
Completed
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
Completed
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
Site data: ClinicalTrials.govUpdated 15 Nov 2026